ImmunoMet Therapeutics from buried science to a story investors lean into.
ImmunoMet is a clinical stage oncology company with a best in class mechanism and genuinely strong data. Their old website and pitch deck made them look like everyone else. We rebuilt both around one idea: the science is the story. A cinematic website to greet investors, and a BIO International deck built to be presented.
World class science, finally dressed to match.
The old site was a 2018 template that buried the story. Here it is, beside the site today, exactly as it lives at immunomet.com.
Science Clinical Pipeline Investors Team About Contact Us
Developing novel cancer drugs by targeting metabolism
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor that targets the metabolic dependency driving cancer-cell survival in resistant tumours.
The old site, then the live site today. Scroll inside either frame.
A clinical first impression, desktop to phone.
One brand language, website to slide.
A single palette and type system, so the company looks like itself everywhere an investor meets it.
The same story, built to be presented.
For BIO International in San Diego, we carried the website's logic into the raise. Open on the gap, land the mechanism, prove it with the trial, then make the ask. Sixteen slides, every one earning the next. Below are real slides from the deck.
From looks like everyone to sounds like a leader.
Have a story worth telling clearly?
If your science is ahead of your slides, that is the gap we close. Website, investor deck, or both.